Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads

Executive Summary

FDA has unveiled the much-anticipated labeling change for GlaxoSmithKline's type 2 diabetes therapy Avandia, but is deeming the information about rosiglitzone's cardiovascular risk "inconclusive" and is asking the sponsor to undertake a long-term outcomes study to address outstanding safety questions

You may also be interested in...



Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure

Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees

GSK Stands By Avandia: Seeks Label Change, Asks Docs To Give It Another Try

Armed with new safety data, GlaxoSmithKline says it remains committed to Avandia, with hopes of a fresh label from the FDA and a change of heart from doctors who had ditched the troubled type 2 diabetes drug

GSK Stands By Avandia: Seeks Label Change, Asks Docs To Give It Another Try

Armed with new safety data, GlaxoSmithKline says it remains committed to Avandia, with hopes of a fresh label from the FDA and a change of heart from doctors who had ditched the troubled type 2 diabetes drug

Related Content

Latest News
UsernamePublicRestriction

Register

PS049015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel